Why the study?
Does periprocedural bridging with dalteparin prevent thromboembolism and minimize bleeding in patients requiring temporary interruption of warfarin?
Population
650 consecutive patients with a mechanical heart valve, chronic atrial fibrillation, or embolic stroke who…
Design
Cohort
Follow-up
mean 13.8 days (range, 10-18 days)
Authors
Loading...
Low event rates with dalteparin bridging may inform periprocedural decisions; leaves open efficacy confirmation in randomized trials.
Does periprocedural bridging with dalteparin prevent thromboembolism and minimize bleeding in patients requiring temporary interruption of warfarin?
A standardized periprocedural bridging regimen with dalteparin is associated with low rates of thromboembolism and major bleeding in patients requiring temporary interruption of warfarin.
Douketis et al. (2004) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: